PubmedID,Title,Publication Date,Non-academic Author(s),Company Affiliation(s),Corresponding Author Email
40624659,One step further in targeting acute leukemia by combining antibody-based immunotherapies and small molecule inhibitors.,2025,N/A,N/A,"Department of Immunology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran. s.taghilo@mazums.ac.ir."
40624624,Integrated analysis of polytranscriptomics reveals TNFSF ligand genes in pancreatic cancer prognosis and immune regulation.,2025,N/A,N/A,"Medical School of Chinese PLA, Beijing, China. liurong301@126.com."
40624569,Recent advances and challenges of cellular immunotherapies in lung cancer treatment.,2025,N/A,N/A,"Medical Center of Hematology, State Key Laboratory of Trauma and Chemical Poisoning, Chongqing Key Laboratory of Hematology and Microenvironment, Xinqiao Hospital of Army Medical University, Chongqing, 400037, China. zhangxxi@sina.com."
40624367,"EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma.",2025,"INSERM UMR-S1277 and CNRS UMR9020, Lille, France.; Department of Medical Oncology and Hematology, HOCH Health Ostchweiz, St. Gallen, Switzerland.; Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy.; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia ""Seràgnoli"", Bologna, Italy.; Centre de Recherche Saint-Antoine INSERM UMRs938, Sorbonne Université, Paris, France.; Clinica Universidad de Navarra, CIMA, IDISNA, CIBERONC, Pamplona, Spain.; Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, Netherlands.; Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France.","Department of Biotechnology and Health Science, University of Torino, Turin, Italy.","Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. eterpos@med.uoa.gr."
40624238,IL-17A-secreting γδ T cells promote resistance to CDK4/CDK6 inhibitors in HR,2025,"Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.; Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), Murcia, Spain.; Department of Anatomy, Physiology and Pathology, Clínica Universidad de Navarra, Pamplona, Spain.; Centro Regional de Hemodonación, Murcia, Spain.; Department of Medicine, Weill Cornell Medicine, New York, NY, USA.; Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.; Department of Medical Biochemistry, Molecular Biology and Immunology, Faculty of Medicine, Universidad de Sevilla, Sevilla, Spain.; Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.; Universidad Católica San Antonio de Murcia, Guadalupe, Spain.; Department of Radiology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.; Sandra and Edward Meyer Cancer Center, New York, NY, USA.; Department of Immunology and Immunotherapy, Clínica Universidad de Navarra, Pamplona, Spain.; Universidad de Murcia, Murcia, Spain.; Department of Radiation Oncology, Clínica Universidad de Navarra, Pamplona, Spain.; Sandra and Edward Meyer Cancer Center, New York, NY, USA. deadoc80@gmail.com.; Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA. deadoc80@gmail.com.",N/A,"Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA. deadoc80@gmail.com."
40624169,Toripalimab in Esophageal Cancer: A Systematic Review and Meta-Analysis.,2025,N/A,N/A,"Faculty of Medicine, Bahri University, Khartoum, Sudan. marafi.ahmed99@gmail.com."
40624082,Targeting dysregulated molecular pathways in cancer cell lines using small molecule inhibitors as a promising therapeutic strategy.,2025,N/A,N/A,"Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Najran University, Najran, Saudi Arabia. hhalmasoudi@nu.edu.sa."
40624019,NR4A3 potentials M1-like macrophage polarization to facilitate anti-tumor immune responses in breast cancer.,2025,N/A,"Cancer Biology Research Center (Key Laboratory of the Ministry of Education, Hubei Provincial Key Laboratory of Tumor Invasion and Metastasis), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. qlgao@tjh.tjmu.edu.cn.; Cancer Biology Research Center (Key Laboratory of the Ministry of Education, Hubei Provincial Key Laboratory of Tumor Invasion and Metastasis), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. Xiayu_hb@tjh.tjmu.edu.cn.; Department of Obstetrics and Gynecology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250000, China.; Cancer Biology Research Center (Key Laboratory of the Ministry of Education, Hubei Provincial Key Laboratory of Tumor Invasion and Metastasis), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.","Cancer Biology Research Center (Key Laboratory of the Ministry of Education, Hubei Provincial Key Laboratory of Tumor Invasion and Metastasis), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. qlgao@tjh.tjmu.edu.cn."
40623945,Cathepsin B-Ignited Nanorocket To Blast Tumor Lysosomes for TLR-Fortified Lysosomal Immunotherapy with Dual-Switchable Fluorescence/Magnetic Resonance Imaging.,2025,N/A,"Key Laboratory of Biomedical Functional Materials, School of Science, China Pharmaceutical University, Nanjing 211198, China.; State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Advanced Pharmaceuticals and Biomaterials, China Pharmaceutical University, Nanjing 211198, China.; Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology, Department of Radiology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China.",N/A
40623912,[Advances in the application strategies of CRISPR/Cas9 technology in chimeric antigen receptor T cell therapy for hematological malignancies].,2025,N/A,"Department/Center of Hematology-oncology, Children's Hospital of Zhejiang University School of Medicine; Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province; National Clinical Research Center for Child Health, Hangzhou 310003, China.",N/A
40623904,[Establishment of a chronic lymphocytic leukemia mouse model via adoptive transfer of Eμ-TCL1 transgenic splenocytes].,2025,N/A,N/A,N/A
40623886,"Platinum and etoposide chemotherapy, durvalumab with thoracic radiotherapy in the first-line treatment of patients with extensive-stage small-cell lung cancer: CHEST-RT (TROG 20.01) Trial - protocol for a phase II study.",2025,"St George Cancer Care Centre, Kogarah, Sydney, Australia.; Radiation Oncology Network, Western Sydney Local Health District, Sydney, New South Wales, Australia.; Trans Tasman Radiation Oncology Group, Waratah, New South Wales, Australia.; Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Olivia Newton-John Cancer Centre at Austin Health, Heidelberg, Victoria, Australia.","Radiation Oncology, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia.; Medical Oncology, St Vincent's Hospital (Melbourne) Limited, Fitzroy, Victoria, Australia.","Radiation Oncology, Blacktown Hospital, Blacktown, New South Wales, Australia eric.hau@health.nsw.gov.au."
40623782,From immunotherapy to autoimmunity: reactive arthritis following intravesical BCG.,2025,N/A,"Surgery, Prince Sattam bin Abdulaziz University, Al Kharj, Saudi Arabia.","Urology, McGill University, Montreal, Quebec, Canada jcorcosmd@gmail.com."
40623769,Role of microbiome in cancer progression.,2025,"NC Flow Cytometry and Cellular Imaging Core Facility, MD Anderson Cancer Center, Houston, TX, United States.",N/A,"Department of Radiation Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX, United States. Electronic address: micro9sadhna@gmail.com."
40623767,The role of microbiome in CAR-T cell therapy.,2025,"Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH, United States.",N/A,"Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer, Houston, TX, United States. Electronic address: Sbentebibel@mdanderson.org."
40623766,The multipotential effect of microbiome in lung cancer development and progression.,2025,N/A,N/A,"Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States; The University of Texas MD Anderson Cancer Center UT Health Houston Graduate School of Biomedical Sciences, Houston, TX, United States. Electronic address: smoghadd@mdanderson.org."
40623765,Gut microbiome and tumor immunotherapy.,2025,N/A,N/A,"Amity Institute of Virology & Immunology, Amity University Uttar Pradesh (AUUP), Sector 125, Noida, Uttar Pradesh, India. Electronic address: sdubey@amity.edu."
40623764,Microbiome-mediated immune modulation in tumor microenvironment.,2025,N/A,N/A,"Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States. Electronic address: adominic@mdanderson.org."
40623719,"Correction: Novel fusion superkine, ",2025,N/A,N/A,N/A
40623718,"Authors response to ""Letter to the Editor"": ""Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types"".",2025,"Foundation Medicine Inc, San Diego, California, USA rgraf@foundationmedicine.com.; Cancer Ctr So./Div of Hem and Onc, UC Davis Department of Medicine, Sacramento, California, USA.","Foundation Medicine Inc, San Diego, California, USA rgraf@foundationmedicine.com.","Foundation Medicine Inc, San Diego, California, USA rgraf@foundationmedicine.com."
40623717,Oncolytic HSV-IL27 expression improves CD8 T cell function and therapeutic activity in syngeneic glioma models.,2025,N/A,N/A,"Center for Childhood Cancer Research, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA Kevin.Cassady@Nationwidechildrens.org."
40623716,Precision targeting of rhabdomyosarcoma by combining primary CAR NK cells and radiotherapy.,2025,"Dr Petra Joh-Haus, Frankfurter Stiftung für krebskranke Kinder, Frankfurt (Main), Germany.; German Cancer Consortium (DKTK), partner site Frankfurt/Mainz, Frankfurt (Main), Germany.",N/A,"Department of Pediatrics, Experimental Immunology and Cell Therapy, Goethe University Frankfurt, Frankfurt (Main), Germany Evelyn@Ullrichlab.de."
40623606,Immunogenicity of neoantigens: From CAR-T cell to various vaccines.,2025,N/A,"Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, NSW 2007, Australia; Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, NSW 2007, Australia. Electronic address: kamal.dua@uts.edu.au.; Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117600 Singapore. Electronic address: phcgs@nus.edu.sg.","Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: davodabadii.fateme@gmail.com."
40623596,Enhancing antigen presentation in cancer stem cells via peptide-based nanoparticles for effective immunotherapy.,2025,N/A,"School of Pharmaceutical Sciences, Sun Yat-sen University, Shenzhen 518107, China.","School of Life Sciences, Zhengzhou University, Zhengzhou 450001, China. Electronic address: wangyongchao@zzu.edu.cn."
40623177,Common inherited loss-of-function mutations in the innate sensor NOD2 contribute to exceptional immune response to cancer immunotherapy.,2025,"Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.; Genentech, South San Francisco, CA 94080-4990.; Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada.; Chris O'Brien Lifehouse, Camperdown, NSW 2050, Australia.; Canberra Region Cancer Centre, Garran, ACT 2605, Australia.","Department of Medical Oncology, The Kinghorn Cancer Centre, St Vincent's Hospital Sydney, Darlinghurst, NSW 2010, Australia.; Department of Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Royal Prince Alfred Hospital, Camperdown, NSW 2050, Australia.; Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada.; Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, NSW 2145, Australia.; St Vincent's Clinical School, University of New South Wales Sydney, Kensington, NSW 2052, Australia.",N/A
40623115,Passive immunotherapy for adults hospitalized with COVID-19: An individual participant data meta-analysis of six randomized controlled trials.,2025,"Ralph H Johnson VA Medical Center, Charleston, South Carolina, United States of America.; Virus Isolation and Serology Laboratory, Frederick National Laboratory, Applied and Developmental Directorate, Frederick, Maryland, United States of America.; Velocity Clinical Research, San Diego, California, United States of America.; Frederick National Laboratory for Cancer Research/Leidos Biomedical Research, Frederick, Maryland, United States of America.; Intermountain Medical Center, Salt Lake City, Utah, United States of America.; Department of Medicine, Division of Pulmonary and Critical Medicine, Duke Medicine, Durham, North Carolina, United States of America.; National Centre for Infectious Diseases, Singapore, Singapore.; Stormont Vail Health, Vail, Colorado, United States of America.",N/A,N/A
40622922,Reply: Clarifying the impact of response criteria and locoregional therapy on complete response outcomes in patients with hepatocellular carcinoma following immunotherapy.,2025,N/A,N/A,N/A
40622715,Multilevel Intervention and Human Papillomavirus Vaccination Disparities: A Secondary Analysis of a Cluster Randomized Trial.,2025,"Division of Community Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota.; Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota.; Division of Epidemiology, Mayo Clinic, Rochester, Minnesota.; Division of Pediatric Infectious Diseases, Mayo Clinic, Rochester, Minnesota.; Division of Health Care Delivery Research and Robert D. and Patricia E. Kern Center for Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota.; Division of Community Internal Medicine, Geriatrics, and Palliative Care, Mayo Clinic, Rochester, Minnesota.; Flying Buttress Associates, Charlottesville, Virginia.",N/A,N/A
40622576,Nephrotoxicity of immunotherapy and targeted therapies used to treat paediatric cancer.,2025,N/A,N/A,"Department of Paediatrics, Division of Paediatric Hematology/Oncology/BMT, University of British Columbia, Vancouver, Canada. rrassekh@cw.bc.ca."
40622562,ASO Author Reflections: From Downstaging to Cure-Conversion Surgery after Trastuzumab-Based Chemo-Immunotherapy for Stage IV HER2-Positive Gastric Cancer.,2025,N/A,"Department of General Surgery and Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, Southern Medical University, Guangdong, China. zlyblue11@163.com.","Department of General Surgery and Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, Southern Medical University, Guangdong, China. zlyblue11@163.com."
40622560,Targeting TP53TG1: a promising prognostic biomarker and therapeutic target for personalized cancer therapy.,2025,N/A,N/A,"Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, 443002, China. 2636095835@qq.com."
40622485,Tumor-associated macrophages and platelets in tumor microenvironment and its potential therapeutic role in ovarian cancer.,2025,N/A,"Key Laboratory of Immune Microenvironment and Inflammatory Disease Research in Universities of Shandong Province, Immunology Laboratory of Shandong Second Medical University, WeifangProvince, 261053, Shandong, China. pmy-107@163.com.; Key Laboratory of Immune Microenvironment and Inflammatory Disease Research in Universities of Shandong Province, Immunology Laboratory of Shandong Second Medical University, WeifangProvince, 261053, Shandong, China. fuxy@sdsmu.edu.cn.; Key Laboratory of Immune Microenvironment and Inflammatory Disease Research in Universities of Shandong Province, Immunology Laboratory of Shandong Second Medical University, WeifangProvince, 261053, Shandong, China.","Key Laboratory of Immune Microenvironment and Inflammatory Disease Research in Universities of Shandong Province, Immunology Laboratory of Shandong Second Medical University, WeifangProvince, 261053, Shandong, China. fuxy@sdsmu.edu.cn."
40622275,Impact of Glucocorticoids on Immune Checkpoint Inhibitor Efficacy and Circulating Biomarkers in Non-Small Cell Lung Cancer Patients.,2025,"Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, New York.; Department of Medical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.; Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.",N/A,N/A
40622253,Novel Autologous Regulatory T-Cell Therapy Ameliorates DSS-Induced Colitis in Humanized Mice.,2025,"Department of Basic Research, PB Immune Therapeutics Inc, Seoul, South Korea.; Preclina Inc., 719 & 1302, Teratower B, 167, Songpa-daero, Songpa-gu, Seoul, South Korea.","Department of Basic Research, PB Immune Therapeutics Inc, Seoul, South Korea.; Preclina Inc., 719 & 1302, Teratower B, 167, Songpa-daero, Songpa-gu, Seoul, South Korea.",N/A
40622083,"Helicobacter pylori infection promotes the formation of the β-catenin/HIF-1α complex, enabling adaptive responses in gastric cancer cells.",2025,"Centro Ciencia & Vida, Fundación Ciencia & Vida, Santiago, Chile.; Faculty of Dentistry, Universidad Andres Bello, Santiago, Chile.; Advanced Center for Chronic Diseases (ACCDiS), Universidad de Chile, Santiago, Chile.; Centro de Biología Celular y Biomedicina (CEBICEM), Facultad de Ciencias, Universidad San Sebastian, Santiago, Chile.; Advanced Scientific Equipment Network (REDECA), Facultad de Medicina, Universidad de Chile, Santiago, Chile.; Faculty of Dentistry, Universidad de La Frontera, Temuco, Chile.",N/A,N/A
40622010,Immune-mediated adverse events in the randomized phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer.,2025,"Department of Medical Oncology, MHAT Nadezhda, Blaga Vest Str, 1330 Sofia, Bulgaria.; Oncology R&D, Late-Stage Development, AstraZeneca, 430 East 29 Street, New York, NY 10016, USA.; Oncology Biometrics, Late Oncology Statistics, AstraZeneca, Postępu 14, 02-676 Warsaw, Poland.; Instituto de Investigaciones Metabólicas, Libertad 836, C1012AAR Cdad, Buenos Aires, Argentina.; Oncology R&D, Late-Stage Development, AstraZeneca, 1 Medimmune Way, Gaithersburg, MD 20878-2204, USA.",N/A,N/A
40621967,[Administration timing may improve the anti-tumor efficacy of immunotherapies].,2025,"Inserm U1331, Institut Curie, MINES ParisTech CBIO - Centre de biologie computationnelle, Université Paris-Sciences-Lettres, équipe Pharmacologie des systèmes contre le cancer, Saint-Cloud, France.","Inserm U1331, Institut Curie, MINES ParisTech CBIO - Centre de biologie computationnelle, Université Paris-Sciences-Lettres, équipe Pharmacologie des systèmes contre le cancer, Saint-Cloud, France.",N/A
40621806,Tumor-Infiltrating Lymphocytes in Breast and Female Genital Tract Cancers: Overlooked Potential and Unexplored Frontiers.,2025,N/A,N/A,N/A
40621766,Lifileucel Therapy for Metastatic Melanoma: Advancements in Tumor-infiltrating Lymphocyte-based Immunotherapy.,2025,N/A,"Department of Pharmacy Practice, ISF College of Pharmacy, Moga, 142001, Punjab, India.; School of Pharmacy, Lingaya's Vidyapeeth, Faridabad, 121002, Haryana, India.; Department of Pharmaceutics, ISF College of Pharmacy, Moga-142001, Punjab, India.; Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, 142001, Punjab, India.",N/A
40621753,Machine Learning-Driven PCDI Classifier for Invasive PitNETs.,2025,N/A,N/A,N/A
40621740,Mature tertiary lymphoid structures linked to HPV status and anti-PD-1 based chemoimmunotherapy response in head and neck squamous cell carcinoma.,2025,"Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.","Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.",N/A
40621483,Immunotherapy in metastatic prostate cancer.,2025,"Cancer Immunology Program, Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Chris O'Brien Lifehouse, 119-143 Missenden Road, Camperdown, NSW 2050, Australia.; Chris O'Brien Lifehouse, Camperdown, NSW, Australia.",N/A,N/A
40621477,Optimization of lentiviral delivery of barcoded anti-CD20 chimeric antigen receptors into rhesus macaque and human natural killer cells.,2025,"Laboratory of Transplantation Immunotherapy, Cellular and Molecular Therapeutics Branch, NHLBI, NIH, Bethesda, MD 20892, USA.; Translational Stem Cell Biology Branch, NHLBI, NIH, Bethesda, MD 20892, USA.",N/A,N/A
40621473,Research progress on the role of dendritic cells in glioma during 1992-2024: a bibliometric analysis.,2025,N/A,N/A,N/A
40621472,"The role of notch signaling pathway and non-coding RNAs in cancer and inflammation: progress, therapeutic insights, and future directions.",2025,N/A,N/A,N/A
40621467,Antibody treatment of hepatocellular carcinoma: a review of current and emerging approaches.,2025,"Immunology Department, Egypt Center for Research and Regenerative Medicine (ECRRM), Cairo, Egypt.","Microbial Biotechnology Department, Biotechnology Research Institute, National Research Centre, Giza, Egypt.",N/A
40621464,Total neoadjuvant immunochemotherapy for proficient mismatch repair or microsatellite stable locally advanced rectal cancer.,2025,N/A,N/A,N/A
40621457,Editorial: Innovative immunotherapy strategies for enhanced treatment of Hodgkin and non-Hodgkin lymphomas.,2025,"Centre d'Immunologie de Marseille-Luminy, Marseille, France.",N/A,N/A
40621454,Case Report: Durable complete response of advanced-stage hepatocellular carcinoma to DEB-TACE combined with lenvatinib and camrelizumab.,2025,"Department of Gastroenterology and Hepatology, Artificial Cell Engineering Technology Research Center, Tianjin, China.",N/A,N/A
40621452,Tumor-suppressing multi-enterobacteria and PD-1/PD-L1 immune checkpoint inhibitor combination improves the outcome of hepatocellular carcinoma therapy.,2025,N/A,N/A,N/A
